TNYA
Tenaya Therapeutics, Inc.
$0.7120
-1.11%
$154.5M
No data for this timeframe.
Vol
Market Cap$154.5M
Cap SizeMicro Cap
Inst. Holders36 funds
Inst. Value$19.3M
Inst. Activity7 buys / 1 sells
Insider Activity0B / 12S
Insider Net $-$2.8M
Reddit Sentiment45° Neutral
SEC Reports8
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001858848·Prev Close $0.7200
Recent Activity
Jun 12, 2026
SEC
Tenaya Therapeutics (TNYA) institutional cluster for Q3 2024 shows net distributing activity, with Adage Capital Partner
INST-CLUSTER — Impact 4/10
Jun 11, 2026
short_volume
Short Volume: TNYA — 69.6% short (1.2M / 1.7M)
Short: 1,215,215 | Exempt: 11,750 | TRF Vol: 1,745,693 | Short Ratio: 69.6% | Off-exchange volume (d
May 28, 2026
Insider
Burroughs Amy L. was granted 120,000 shares
Director
May 28, 2026
Insider
Lee June was granted 120,000 shares
Director
May 28, 2026
Insider
Parschauer Karah Herdman was granted 120,000 shares
Director
May 16, 2026
SEC
William Blair initiates Tenaya Therapeutics at Outperform — consensus already heavily bullish, stock at $0.94
ANALYST-UPGRADE — Impact 1/10
Apr 16, 2026
SEC
William Blair initiates TNYA at Outperform with no price target — current price $0.77 vs. $9 mean PT
ANALYST-UPGRADE — Impact 1/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
3,713,761 shares ($2.6M)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$4.00 (Mar 2026)
Current $0.7118
Low $2.00
Median $3.50
High $8.00
6 analysts
$2.00
$8.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Dec 18, 2025 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▲ +39.7% | $-0.14 — $-0.04 | 54% YoY | 7 |
| Next Q | $-0.10 ▲ +16.7% | $-0.14 — $-0.08 | 18% YoY | 7 |
| Current FY | $-0.38 ▲ +10.8% | $-0.59 — $-0.27 | 35% YoY | 8 |
| Next FY | $-0.41 ▲ +8.4% | $-0.59 — $-0.29 | -8% YoY | 5 |
Latest Reports
BULLISH
ANALYST-UPGRADE
1/10
William Blair initiates Tenaya Therapeutics at Outperform — consensus already heavily bullish, stock at $0.94
May 16, 2026
MIXED
ANALYST-UPGRADE
1/10
William Blair initiates TNYA at Outperform with no price target — current price $0.77 vs. $9 mean PT
Apr 16, 2026
MIXED
Press
6/10
Tenaya Therapeutics reported financial results for Q4 and full year 2025, highlighted by reduced net loss and a strength
Mar 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $5.9M | — |
| CITADEL ADVISORS LLC | $2.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $2.6M | DOUBLED |
| BlackRock, Inc. | $2.6M | ADD |
| MARSHALL WACE, LLP | $1.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | Burroughs Amy | A | $0.00 |
| May 28, 2026 | Lee June | A | $0.00 |
| May 28, 2026 | Parschauer Karah | A | $0.00 |
| May 28, 2026 | Srivastava Deepak | A | $0.00 |
| May 28, 2026 | Stehman-Breen Catherine | A | $0.00 |
Reddit Sentiment
45°▼
Neutral
Bearish
Neutral
Bullish
36 institutional holders with $19.3M total value (27,872,836 shares) as of 2026-Q1. Top holders: VANGUARD, CITADEL, RENAISSANCE. Net buying activity: 7 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 8,482,288 | $5.9M | 30.5% | — |
| 2 | CITADEL ADVISORS LLC | 4,200,000 | $2.9M | 15.1% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 3,713,761 | $2.6M | 13.3% | DOUBLED +100.6% |
| 4 | BlackRock, Inc. | 3,703,955 | $2.6M | 13.3% | ADD +69.7% |
| 5 | MARSHALL WACE, LLP | 2,705,390 | $1.9M | 9.7% | ADD +92.4% |
| 6 | TWO SIGMA INVESTMENTS, LP | 1,280,390 | $886.5K | 4.6% | ADD +39.0% |
| 7 | VANGUARD FIDUCIARY TRUST CO | 1,015,702 | $702.9K | 3.6% | — |
| 8 | STATE STREET CORP | 708,721 | $490.7K | 2.5% | ADD +59.0% |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 308,772 | $213.8K | 1.1% | — |
| 10 | MORGAN STANLEY | 268,505 | $185.9K | 1.0% | ADD +28.8% |
| 11 | Marex Group plc | 235,500 | $163.1K | 0.8% | ADD +27.3% |
| 12 | OMERS ADMINISTRATION Corp | 207,100 | $143.4K | 0.7% | — |
| 13 | CITADEL ADVISORS LLC | 176,000 | $121.9K | 0.6% | — |
| 14 | GOLDMAN SACHS GROUP INC | 154,801 | $107.2K | 0.6% | — |
| 15 | Invesco Ltd. | 138,006 | $95.6K | 0.5% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 70,100 | $48.4K | 0.3% | — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 64,904 | $44.9K | 0.2% | TRIM -25.1% |
| 18 | Vanguard Personalized Indexing Management, LLC | 53,939 | $37.3K | 0.2% | ADD +33.8% |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 53,900 | $37.2K | 0.2% | — |
| 20 | Vanguard Global Advisers, LLC | 50,070 | $34.6K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 1,850,867 | 3,713,761 | +100.6% | $2.6M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 1,406,035 | 2,705,390 | +92.4% | $1.9M | 2026-Q1 |
| STATE STREET CORP | ADD | 445,821 | 708,721 | +59.0% | $490.7K | 2026-Q1 |
| MORGAN STANLEY | ADD | 208,431 | 268,505 | +28.8% | $185.9K | 2026-Q1 |
| Marex Group plc | ADD | 185,011 | 235,500 | +27.3% | $163.1K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 9,508 | 22,961 | +141.5% | $15.9K | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 8,091 | 11,306 | +39.7% | $7.8K | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 1,559 | 251 | -83.9% | $174.00 | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 5,064,857 | 8,560,108 | +69.0% | $6.1M | 2025-Q4 |
| BlackRock, Inc. | ADD | 2,327,201 | 3,948,586 | +69.7% | $2.8M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 17,285 | 1,406,035 | +8034.4% | $998.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 910,568 | 1,266,075 | +39.0% | $900.8K | 2025-Q4 |
| Marex Group plc | TRIM | 302,500 | 185,011 | -38.8% | $131.6K | 2025-Q4 |
| COMMERCE BANK | TRIM | 25,000 | 15,000 | -40.0% | $10.7K | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 32,706 | 9,508 | -70.9% | $6.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,000 | 4,000 | +300.0% | $2.8K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 14,639 | 1,559 | -89.4% | $1.00 | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 474,787 | 910,568 | +91.8% | $1.5M | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 209,821 | 445,821 | +112.5% | $722.2K | 2025-Q3 |
| Marex Group plc | TRIM | 412,500 | 302,500 | -26.7% | $490.1K | 2025-Q3 |
| UBS Group AG | ADD | 120,176 | 196,727 | +63.7% | $318.7K | 2025-Q3 |
| MORGAN STANLEY | ADD | 115,879 | 167,089 | +44.2% | $270.7K | 2025-Q3 |
| GROUP ONE TRADING LLC | ADD | 18,150 | 32,706 | +80.2% | $53.0K | 2025-Q3 |
| Mariner, LLC | TRIM | 41,418 | 20,393 | -50.8% | $33.0K | 2025-Q3 |
| MARSHALL WACE, LLP | NEAR_EXIT | 148,089 | 17,285 | -88.3% | $28.0K | 2025-Q3 |
11 unique insiders with 25 transactions. Net insider value: -$2.8M ($0.00 bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | Burroughs Amy L. | Director | AWARD | 120,000 | — | — |
| May 28, 2026 | Lee June | Director | AWARD | 120,000 | — | — |
| May 28, 2026 | Parschauer Karah Herdman | Director | AWARD | 120,000 | — | — |
| May 28, 2026 | Srivastava Deepak | Director | AWARD | 120,000 | — | — |
| May 28, 2026 | Stehman-Breen Catherine | Director | AWARD | 120,000 | — | — |
| May 28, 2026 | Walsh Jeffrey T. | Director | AWARD | 120,000 | — | — |
| May 28, 2026 | Williams R Sanders | Director | AWARD | 120,000 | — | — |
| May 18, 2026 | Tingley Whittemore | Chief Medical Officer | SELL | 3,121 | $0.7936 | $2.5K |
| May 18, 2026 | Higa Tomohiro | SVP, Finance | SELL | 1,485 | $0.7932 | $1.2K |
| May 18, 2026 | Ali Faraz | Chief Executive Officer | SELL | 3,390 | $0.7934 | $2.7K |
| Feb 25, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 1,649,281 | $0.5624 | $927.6K |
| Feb 24, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 309,228 | $0.6153 | $190.3K |
| Feb 23, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 143,709 | $0.5972 | $85.8K |
| Feb 20, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 245,965 | $0.6149 | $151.2K |
| Feb 17, 2026 | Higa Tomohiro | SVP, Finance | SELL | 611 | $0.6434 | $393.12 |
| Feb 17, 2026 | Tingley Whittemore | Chief Medical Officer | SELL | 1,642 | $0.6432 | $1.1K |
| Feb 17, 2026 | Ali Faraz | Chief Executive Officer | SELL | 5,851 | $0.6430 | $3.8K |
| Feb 11, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 1,905,115 | $0.6808 | $1.3M |
| Feb 10, 2026 | COLUMN GROUP III GP, LP | 10%+ Owner | SELL | 161,422 | $0.8161 | $131.7K |
| Feb 3, 2026 | Ali Faraz | Chief Executive Officer | AWARD | 158,600 | — | — |
| Feb 3, 2026 | Ali Faraz | Chief Executive Officer | AWARD | 952,250 | — | — |
| Feb 3, 2026 | Higa Tomohiro | SVP, Finance | AWARD | 29,250 | — | — |
| Feb 3, 2026 | Higa Tomohiro | SVP, Finance | AWARD | 175,500 | — | — |
| Feb 3, 2026 | Tingley Whittemore | Chief Medical Officer | AWARD | 48,750 | — | — |
| Feb 3, 2026 | Tingley Whittemore | Chief Medical Officer | AWARD | 318,500 | — | — |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 4 neutral. Avg impact: 3.3/10.
MIXED
ANALYST-UPGRADE
1/10
William Blair initiates TNYA at Outperform with no price target — current price $0.77 vs. $9 mean PT
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
1/10
William Blair initiates Tenaya Therapeutics at Outperform — consensus already heavily bullish, stock at $0.94
May 16, 2026
BEARISH
INST-CLUSTER
4/10
Tenaya Therapeutics (TNYA) institutional cluster for Q3 2024 shows net distributing activity, with A
Jun 12, 2026
NEUTRAL
8-K
3/10
Tenaya Therapeutics held its 2026 annual meeting on May 27, 2026, where shareholders approved an ame
May 29, 2026
NEUTRAL
CLUSTER
2/10
Two Tenaya insiders (CMO and SVP Finance) sold a combined $3.7K worth of shares on May 18, 2026, all
May 19, 2026
NEUTRAL
DEFA14A
3/10
Tenaya Therapeutics is holding its annual shareholder meeting to elect three directors, ratify its a
Apr 16, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K indicates a repor
Mar 11, 2026
BULLISH
8-K
8/10
Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceuticals to discover
Mar 5, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 93% buy across 14 analysts — 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$4.00 mean target (Mar 2026)
$2.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $0.7118 |
| Target Low | $2.00 |
| Target Mean | $4.00 |
| Target Median | $3.50 |
| Target High | $8.00 |
| # Analysts | 6 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.14 | $-0.04 | 54.1% | +39.7% | 1↑ 0↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.10 | $-0.14 | $-0.08 | 17.9% | +16.7% | 4↑ 0↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-0.38 | $-0.59 | $-0.27 | 35.2% | +10.8% | 4↑ 0↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-0.41 | $-0.59 | $-0.29 | -8.2% | +8.4% | 0↑ 1↓ | $0.0B | -100.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.064 | |
| 7d ago | $-0.064 | |
| 30d ago | $-0.107 | +0.042 |
| 60d ago | $-0.107 | +0.042 |
| 90d ago | $-0.130 | +0.066 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
45°
Neutral
Bearish
Neutral
Bullish
6 mentions
0 bullish
1 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 10, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 15, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 11, 2026
short_volume
Short Volume: TNYA — 69.6% short (1.2M / 1.7M)
Short: 1,215,215 | Exempt: 11,750 | TRF Vol: 1,745,693 | Short Ratio: 69.6% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: TNYA — 56.4% short (1.1M / 1.9M)
Short: 1,079,149 | Exempt: 8,152 | TRF Vol: 1,913,399 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: TNYA — 57.7% short (1.7M / 2.9M)
Short: 1,670,250 | Exempt: 46,408 | TRF Vol: 2,892,794 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: TNYA — 61.0% short (1.9M / 3.0M)
Short: 1,851,297 | Exempt: 70,455 | TRF Vol: 3,036,913 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
other
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
<p align="center"><em>All Evaluable Patients Achieved Improvements in Multiple Hallmarks of </em><br><em>MYBPC3-Associated HCM </em></p>
Jun 3, 2026
short_volume
Short Volume: TNYA — 67.2% short (2.2M / 3.3M)
Short: 2,204,200 | Exempt: 26,777 | TRF Vol: 3,278,920 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
routine
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET <pre>Management to host webcast on Wednesday, June 3 at 8:00 a.m. ET</pre>
Jun 1, 2026
short_volume
Short Volume: TNYA — 65.1% short (2.1M / 3.2M)
Short: 2,098,746 | Exempt: 36,166 | TRF Vol: 3,223,774 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
other
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
<p>SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company wi
May 29, 2026
short_volume
Short Volume: TNYA — 59.2% short (1.7M / 3.0M)
Short: 1,749,933 | Exempt: 422 | TRF Vol: 2,954,663 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: TNYA — 58.7% short (1.1M / 1.8M)
Short: 1,078,880 | Exempt: 0 | TRF Vol: 1,838,161 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: TNYA — 63.6% short (0.8M / 1.2M)
Short: 756,211 | Exempt: 92,535 | TRF Vol: 1,189,264 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: TNYA — 59.9% short (2.0M / 3.4M)
Short: 2,046,950 | Exempt: 340,147 | TRF Vol: 3,417,875 | Short Ratio: 59.9% | Off-exchange volume (dark pool + OTC)
May 15, 2026
other
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
<p align="center"><em>All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count </em></p>
May 13, 2026
earnings_calendar
TNYA Q1 2026 Earnings Scheduled — 2026-05-13